Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 39 Records)
|Query Trace: Lung Neoplasms and Mos[original query]|
| Cytoplasmic expression of estrogen receptor ? may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma.
Oncology letters 2018 Aug 16 (2): 2382-2390.
Ding Xiaosheng, Li Li, Tang CHuanhao, Meng Chao, Xu Weiran, Wei Xing, Guo Ziwei, Zhang Tingting, Fu Yali, Zhang Lingling, Wang Xiangyi, Lin Li, Liang J
| Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
Archives of medical science : AMS 2018 11 14 (6): 1298-1307.
Wang Wenxian, Song Zhengbo, Zhang Yipi
| Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
PloS one 2019 14 (8): e0220691.
Grosse Claudia, Soltermann Alex, Rechsteiner Markus, Grosse Alexand
| Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
Cancer management and research 2019 11 5665-5675.
Hou Helei, Qin Kang, Liang Yu, Zhang Chuantao, Liu Dong, Jiang Haiping, Liu Kewei, Zhu Jingjuan, Lv Hongying, Li Tianjun, Zhang Xiaoch
| Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Lung cancer (Amsterdam, Netherlands) 2019 Jul 133 96-102.
Awad Mark M, Leonardi Giulia C, Kravets Sasha, Dahlberg Suzanne E, Drilon Alexander, Noonan Sinead A, Camidge D Ross, Ou Sai-Hong I, Costa Daniel B, Gadgeel Shirish M, Steuer Conor E, Forde Patrick M, Zhu Viola W, Fukuda Yoko, Clark Jeffrey W, Jänne Pasi A, Mok Tony, Sholl Lynette M, Heist Rebecca
| Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Journal for immunotherapy of cancer 2019 3 7 (1): 87.
Ricciuti Biagio, Kravets Sasha, Dahlberg Suzanne E, Umeton Renato, Albayrak Adem, Subegdjo Safiya J, Johnson Bruce E, Nishino Mizuki, Sholl Lynette M, Awad Mark
| Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Journal of translational medicine 2019 2 17 (1): 52.
Wang Wenxian, Wang Hong, Lu Peihua, Yu Zongyang, Xu Chunwei, Zhuang Wu, Song Zheng
| Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis.
Lung Cancer (Auckland, N.Z.) 2019 10 1-10.
Kate Shruti, Chougule Anuradha, Joshi Amit, Noronha Vanita, Patil Vijay, Dusane Rohit, Solanki Leena, Tiwrekar Priyanka, Trivedi Vaishakhi, Prabhash Kum
| Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation.
OncoTargets and therapy 2019 12 12 8863-8871.
Zhou Shaozhang, Wang Huilin, Jiang Wei, Yu Qit
| Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
Asian Pacific journal of cancer prevention : APJCP 2019 Dec 20 (12): 3581-3589.
Incharoen Pimpin, Charonpongsuntorn Chanchai, Saowapa Sakditat, Sirachainan Ekaphop, Dejthevaporn Thitiya, Kampreasart Kaettipong, Trachu Narumol, Muntham Dittapol, Reungwetwattana Thanyan
| Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
Radiology and oncology 2019 Nov 53 (4): 453-458.
Stanic Karmen, Turnsek Nina, Vrankar Marti
| Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Oncology research 2019 Oct .
Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuank
| [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Zhonghua yi xue za zhi 2019 1 99 (2): 99-104.
Fan H J, Yuan J, Wu J J, Jia Y X, Ma Y H, Li X
| Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
BMC cancer 2020 Sep 20 (1): 837.
Wang Jing, Liu Zhiyan, Pang Qingsong, Zhang Tian, Chen Xi, Er Puchun, Wang Yuwen, Wang Ping, Wang J
| Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Jul .
Lee Jiyun, Choi Yoon La, Han Joungho, Park Sehhoon, Jung Hyun Ae, Su Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Park Keunchil, Ahn Myung-
| Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status.
Evidence-based complementary and alternative medicine : eCAM 2021 8 2021 6968194.
Zhang Milan, Ma Weifeng, Liu Huiqin, Jiang Yushu, Qin Lingzhi, Li Wei, Zhang Jiew
| Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.
Frontiers in public health 2021 9 677862.
Wang Yujia, Wu Guoyu, Li Ru, Luo Yingzhe, Huang Xingmei, He Lifang, Zhong Huihui, Xiong Shaoqu
| Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Anti-cancer agents in medicinal chemistry 2021 7 22 (7): 1278-1285.
Tibaldi Carmelo, Mazzoni Francesca, Scotti Vieri, Vasile Enrico, Pozzessere Daniele, Stasi Irene, Camerini Andrea, Federici Francesca, Meoni Giulia, Caparello Chiara, Turrini Marianna, Rossi Virginia, Ciccone Lucia Pia, Pecora Irene, Fantechi Beatrice, Antonuzzo Lorenzo, Giannarelli Diana, Baldini Edit
| SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Apr .
Alessi Joao V, Ricciuti Biagio, Spurr Liam F, Gupta Hersh, Li Yvonne Y, Glass Carolyn, Nishino Mizuki, Cherniack Andrew D, Lindsay James, Sharma Bijaya, Felt Kristen D, Rodig Scott J, Cheng Michael L, Sholl Lynette M, Awad Mark
| Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ?50%: real-world data.
Oncoimmunology 2021 2 10 (1): 1865653.
Dudnik Elizabeth, Moskovitz Mor, Rottenberg Yakir, Lobachov Anastasiya, Mandelboim Rinat, Shochat Tzippy, Urban Damien, Wollner Mira, Nechushtan Hovav, Rotem Ofer, Zer Alona, Daher Sameh, Bar Jair,
| Albumin-to-alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation-negative advanced non-small cell lung cancer.
The clinical respiratory journal 2021 2 15 (5): 540-549.
Liu Xiaoqin, Li Yan, Zhao Qi, Jiang Hanyi, Ni Jun, Cai Houro
| Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
Frontiers in oncology 2021 12 11 739090.
Tian Tian, Yu Min, Li Juan, Jiang Maoqiong, Ma Daiyuan, Tang Shubin, Lin Zhiyu, Chen Lin, Gong Youling, Zhu Jiang, Zhou Qiang, Huang Meijuan, Lu Y
| Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma.
Chinese medical journal 2021 Sep 134 (20): 2430-2437.
Liu Xiang-Liang, Bai Ri-Lan, Chen Xiao, Zhao Yu-Guang, Wang Xu, Ma Ke-Wei, Tian Hui-Min, Han Fu-Jun, Liu Zi-Ling, Yang Lei, Li Wei, Gai Fei, Cui Jiu-W
| Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Lung cancer (Amsterdam, Netherlands) 2022 10 172 86-93.
Wang Chunsheng, Zhao Kewei, Hu Shanliang, Dong Wei, Gong Yan, Li Minghuan, Xie Congh
| Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.
Cancer medicine 2022 Jun .
Hu Chunhong, Wu Sixuan, Deng Renfang, Wu Yuanqiang, Pan Yue, Shu Long, Wu Fa
| Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
Translational lung cancer research 2022 3 11 (2): 201-212.
Lv Weize, Pei Xiaofeng, Zhao Wenhua, Cong Yunyan, Wei Yajun, Li Ting, Zhang Hongyu, Lin Zhong, Saito Yuichi, Kim Jae Jun, Liang Zibin, Zhong Beilong, Wang Zhih
| Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study.
Technology in cancer research & treatment 2022 12 21 15330338221138213.
Cao Jin, J Gu Juan, Liang Yichen, Wang Buh
| The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
Cancer medicine 2022 11 .
Yu Xiaoqing, Si Jinfei, Wei Jingwen, Wang Yanling, Sun Yan, Jin Jianan, Zhang Xiaoyan, Ma Tonghui, Song Zheng
| Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
Thoracic cancer 2023 4 .
Zhang Ling, You Yunhong, Liu Xueli, Liu Fengjuan, Nie Keke, Ji Youx
| DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.
Translational lung cancer research 2023 1 11 (12): 2539-2566.
Xiao Zhiwei, Sun Lingling, Zheng Yating, Chen Hanrui, Zheng Xinting, Luo Jiamin, Gu Chuying, Lin Ruiting, Huang Mengli, Bai Yuezong, Chen Zhe-Sheng, Kinslow Connor J, Loh Jerold, Lin Liz
- Page last reviewed:Feb 1, 2023
- Page last updated:Jun 02, 2023
- Content source: